Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Tortorici

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Clinical Pharmacology in Drug Development|April 30, 2016
The effect of rifampin on the pharmacokinetics of sirolimus in healthy volunteersMichael A Tortorici, Kyle Matschke, Joan M Korth-Bradley, et al.
Clinical Pharmacokinetics|May 17, 2013
Clinical pharmacology of axitinibYing Chen, Michael A Tortorici, May Garrett, et al.
Blood Advances|September 8, 2020
Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2Ravi Sarode, Katsuyuki Fukutake, Masahiro Yasaka, et al.
Journal of Clinical Pharmacology|December 16, 2014
Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney diseaseMichael A Tortorici, David L Cutler, Anasuya Hazra, et al.
Journal of Clinical Pharmacology|November 20, 2018
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux CapacityAndreas Gille, Danielle Duffy, Michael A Tortorici, et al.
Cancer Chemotherapy and Pharmacology|January 16, 2015
Effect of axitinib on the QT interval in healthy volunteersAna Ruiz-Garcia, Brett E Houk, Yazdi K Pithavala, et al.
Investigational New Drugs|February 10, 2015
Axitinib plasma pharmacokinetics and ethnic differencesYing Chen, Akiyuki Suzuki, Michael A Tortorici, et al.
British Journal of Clinical Pharmacology|November 20, 2020
Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patientsBo Zheng, Danielle Duffy, Pierluigi Tricoci, et al.
International Immunopharmacology|November 18, 2018
Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiencyMichael A Tortorici, John-Philip Lawo, Rudolf Weide, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2014
Pharmacokinetics of single-agent axitinib across multiple solid tumor typesMichael A Tortorici, Ezra E W Cohen, Yazdi K Pithavala, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Clinical Pharmacology in Drug Development|April 30, 2016
The effect of rifampin on the pharmacokinetics of sirolimus in healthy volunteersMichael A Tortorici, Kyle Matschke, Joan M Korth-Bradley, et al.
Clinical Pharmacokinetics|May 17, 2013
Clinical pharmacology of axitinibYing Chen, Michael A Tortorici, May Garrett, et al.
Blood Advances|September 8, 2020
Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2Ravi Sarode, Katsuyuki Fukutake, Masahiro Yasaka, et al.
Journal of Clinical Pharmacology|December 16, 2014
Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney diseaseMichael A Tortorici, David L Cutler, Anasuya Hazra, et al.
Journal of Clinical Pharmacology|November 20, 2018
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux CapacityAndreas Gille, Danielle Duffy, Michael A Tortorici, et al.
Cancer Chemotherapy and Pharmacology|January 16, 2015
Effect of axitinib on the QT interval in healthy volunteersAna Ruiz-Garcia, Brett E Houk, Yazdi K Pithavala, et al.
Investigational New Drugs|February 10, 2015
Axitinib plasma pharmacokinetics and ethnic differencesYing Chen, Akiyuki Suzuki, Michael A Tortorici, et al.
British Journal of Clinical Pharmacology|November 20, 2020
Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patientsBo Zheng, Danielle Duffy, Pierluigi Tricoci, et al.
International Immunopharmacology|November 18, 2018
Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiencyMichael A Tortorici, John-Philip Lawo, Rudolf Weide, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2014
Pharmacokinetics of single-agent axitinib across multiple solid tumor typesMichael A Tortorici, Ezra E W Cohen, Yazdi K Pithavala, et al.
Pageof 4